CA2323047C - Promedicaments d'antagonistes nk, de carbamate benzofuranylmethyl - Google Patents

Promedicaments d'antagonistes nk, de carbamate benzofuranylmethyl Download PDF

Info

Publication number
CA2323047C
CA2323047C CA002323047A CA2323047A CA2323047C CA 2323047 C CA2323047 C CA 2323047C CA 002323047 A CA002323047 A CA 002323047A CA 2323047 A CA2323047 A CA 2323047A CA 2323047 C CA2323047 C CA 2323047C
Authority
CA
Canada
Prior art keywords
compound according
compound
pharmaceutically acceptable
phenyl
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002323047A
Other languages
English (en)
Other versions
CA2323047A1 (fr
Inventor
Oilun Helen Chan
Michael Huai Gu Chen
Om Prakash Goel
Fred M. Hershenson
Zhijian Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CA2323047A1 publication Critical patent/CA2323047A1/fr
Application granted granted Critical
Publication of CA2323047C publication Critical patent/CA2323047C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des promédicaments de certains antagonistes de tachykinine (antagonistes NK1), solubles dans un milieu aqueux, et utiles dans le traitement des vomissements, représentés par la formule (I), ou un sel pharmaceutiquement acceptable de ceux-ci. Dans cette formule, R représente CH2OZ, -C(=O)OCH2OZ ou Z représente (a), -P(=O)(OH)2 ou -C(=O)Q:; n est un nombre entier compris entre 0 et 3; m est un nombre entier compris entre 0 et 1.
CA002323047A 1998-04-15 1999-03-19 Promedicaments d'antagonistes nk, de carbamate benzofuranylmethyl Expired - Fee Related CA2323047C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8188198P 1998-04-15 1998-04-15
US60/081,881 1998-04-15
PCT/US1999/006041 WO1999052903A1 (fr) 1998-04-15 1999-03-19 Promedicaments d'antagonistes nk1 de carbamate benzofuranylmethyl

Publications (2)

Publication Number Publication Date
CA2323047A1 CA2323047A1 (fr) 1999-10-21
CA2323047C true CA2323047C (fr) 2005-03-15

Family

ID=22167001

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323047A Expired - Fee Related CA2323047C (fr) 1998-04-15 1999-03-19 Promedicaments d'antagonistes nk, de carbamate benzofuranylmethyl

Country Status (6)

Country Link
US (1) US6258800B1 (fr)
EP (1) EP1075472A1 (fr)
JP (1) JP2002511467A (fr)
AU (1) AU3011499A (fr)
CA (1) CA2323047C (fr)
WO (1) WO1999052903A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355137A1 (fr) * 1998-12-18 2000-06-29 Martyn Clive Pritchard Antagonistes des recepteurs nk1 non peptidiques
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7776855B2 (en) 2006-07-27 2010-08-17 Janssen Pharmaceutica N.V. Antimicrobial oxazolidinone prodrugs
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
CA2716347C (fr) * 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Inhibiteurs aminoacides du cytochrome p450
JP6397010B2 (ja) 2013-07-03 2018-09-26 カリオファーム セラピューティクス，インコーポレイテッド 置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用
JP7849948B2 (ja) * 2018-03-05 2026-04-22 テオン セラピューティクス，インク． アデノシン受容体アンタゴニストおよびその使用
US20220213099A1 (en) * 2019-05-07 2022-07-07 Bristol-Myers Squibb Company Prodrug compounds
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3475065D1 (en) * 1983-06-23 1988-12-15 Merck & Co Inc (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4760057A (en) * 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
CA2140640A1 (fr) * 1992-08-13 1994-03-03 David C. Horwell Antagonistes de la tachykinine
EP0912173A1 (fr) * 1996-06-26 1999-05-06 Warner-Lambert Company Utilisation d'un antagoniste de la tachykinine pour la confection d'un medicament actif contre le vomissement

Also Published As

Publication number Publication date
WO1999052903A1 (fr) 1999-10-21
CA2323047A1 (fr) 1999-10-21
AU3011499A (en) 1999-11-01
EP1075472A1 (fr) 2001-02-14
JP2002511467A (ja) 2002-04-16
US6258800B1 (en) 2001-07-10

Similar Documents

Publication Publication Date Title
DE69020918T2 (de) Decahydroisoquinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
JP3315463B2 (ja) 環状イミノ誘導体、それらの調製法及びこれらの化合物を含む医薬組成物
EP0272208B1 (fr) Acides azacycloalkylalcanediphosphoniques substitués aromatiquement
WO1998017672A1 (fr) Acides aminoalcanophosphoniques substitues
JP2005526097A (ja) フルオロオキシインドールのホスフェートプロドラッグ
EP0539503B1 (fr) Antagonistes des acides amines excitateurs
US6258800B1 (en) Prodrugs of benzofuranylethyl carbamate NK1 antagonists
DE3512536A1 (de) Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
NZ226089A (en) Pyrimidinylamino derivatives of substituted piperidine; pharmaceutical compositions and processes of preparation
JP2004504323A (ja) インドロキナゾリノン類
AU657018B2 (en) Guanidinoalkyl-1, 1-bisphosphonic acid derivatives, process for their preparation and their use
CN108473532A (zh) 硼替佐米缀合物和其使用方法
EP0320455A1 (fr) Acides aminoalcanediphosphoniques araliphatiques
EP0317505A1 (fr) Acides azacycloalkylalcanediphosphoniques
JPS61100564A (ja) ペプチドで置換された複素環免疫促進剤
FR2821356A1 (fr) Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
JP2934295B2 (ja) Ｎｍｄａ拮抗体
US5710139A (en) Heterocyclic compounds
DE69115116T2 (de) Heterocyclische NMDA Antagonisten.
EP0391850B1 (fr) Dérivés amino-dicarboxyliques insaturés
US5500419A (en) NMDA antagonists
PT97281A (pt) Processo para a preparacao de novos derivados contendo fosforo
JP2004506715A (ja) Ｎｍｄａ受容体リガンドに対するプロドラッグ
CN1061595A (zh) 用作兴奋氨基酸受体拮抗剂的新杂环族化合物及其制备方法和用途
HRP20020513A2 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed